 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol IDs
|
|
|
| |
Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer
|
|
|
|
Phase III, Phase II
|
|
|
|
HFHS 05-03
NCT00448240
|
|
| |
Comparison of Gene Therapy With Chemotherapy in Treating Patients With Head and Neck Cancer
|
|
|
|
Phase III
|
|
|
|
INTROGEN-T301
NCT00041613
|
|
| |
Chemotherapy With or Without Gene Therapy in Treating Patients With Unresectable Recurrent Head and Neck Cancer
|
|
|
|
Phase III
|
|
|
|
INTROGEN-T302
UCLA-0312111-01, NCT00041626
|
|
| |
Study Of Zd1839 (Iressa™) Versus Methotrexate For Previously Treated Patients With Squamous Cell Carcinoma Of The Head And Neck
|
|
|
|
Phase III
|
|
|
|
ZD1839IL/0704
NCT00072878
|
|
| |
Docetaxel With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer
|
|
|
|
Phase III
|
|
|
|
ECOG-E1302
E1302, NCT00088907
|
|
| |
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
|
|
|
|
Phase III
|
|
|
|
ECOG-E1305
E1305, NCT00588770
|
|
| |
Nutrition and Resistance Training in Head and Neck Cancer
|
|
|
|
Phase III
|
|
|
|
080219
NCT00696553
|
|
| |
Erlotinib and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
|
|
|
|
Phase II, Phase I
|
|
|
|
VU-VICC-GI-0622
VICC-GI-0622, 6980, NCI-6980, NCT00397384
|
|
| |
Radiotherapy, Cetuximab, and Injections of TNFerade™ Biologic for Elderly or Frail Patients With Head and Neck Cancer
|
|
|
|
Phase II, Phase I
|
|
|
|
UCIRB #14735B
GV-001.010 (TNF-ELF), NCT00496236
|
|
| |
A Study of TNFerade™ Biologic With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) in Patients With Head and Neck Cancer
|
|
|
|
Phase II, Phase I
|
|
|
|
UCIRB #14733B
GV-001.011 (TNF-CORE), NCT00496535
|
|
